GlaxoSmithKline Shares Outstanding 2006-2018 | GSK

GlaxoSmithKline shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • GlaxoSmithKline shares outstanding for the quarter ending September 30, 2018 were 2.459B, a 0.36% decline year-over-year.
  • GlaxoSmithKline 2017 shares outstanding were 2.471B, a 0.65% increase from 2016.
  • GlaxoSmithKline 2016 shares outstanding were 2.455B, a 0.43% increase from 2015.
  • GlaxoSmithKline 2015 shares outstanding were 2.444B, a 0.47% increase from 2014.
GlaxoSmithKline Annual Shares Outstanding
(Millions of Shares)
2017 2,471
2016 2,455
2015 2,444
2014 2,433
2013 2,460
2012 2,456
2011 2,550
2010 2,564
2009 2,596
2008 2,598
2007 5,679
2006 5,757
2005 2,916
GlaxoSmithKline Quarterly Shares Outstanding
(Millions of Shares)
Q3 2018 2,459
Q2 2018 2,481
Q1 2018 2,473
Q4 2017 2,471
Q3 2017 2,468
Q2 2017 2,444
Q1 2017 2,459
Q4 2016 2,455
Q3 2016 2,451
Q2 2016 2,430
Q1 2016 2,445
Q4 2015 2,419
Q3 2015 2,439
Q2 2015 2,437
Q1 2015 2,410
Q4 2014 2,405
Q3 2014 2,433
Q2 2014 2,406
Q1 2014 2,438
Q4 2013 2,387
Q3 2013 2,462
Q2 2013 2,465
Q1 2013 2,424
Q4 2012 2,422
Q3 2012 2,486
Q2 2012 2,495
Q1 2012 2,481
Q4 2011 2,513
Q3 2011 2,536
Q2 2011 2,537
Q1 2011 2,569
Q4 2010 2,566
Q3 2010 2,669
Q2 2010 2,372
Q1 2010 2,582
Q4 2009 2,619
Q3 2009 2,618
Q2 2009 2,582
Q1 2009 2,627
Q4 2008 2,552
Q3 2008 2,656
Q2 2008 2,653
Q1 2008 2,803
Q4 2007 5,626
Q3 2007 2,834
Q2 2007 2,823
Q1 2007 2,826
Q4 2006 5,738
Q3 2006 2,925
Q2 2006 2,870
Q1 2006 2,886
Q4 2005 2,910
Q3 2005 2,944
Q2 2005 2,921
Q1 2005 2,899
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $100.041B $38.892B
GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $391.677B 18.36
Pfizer (PFE) United States $259.009B 14.60
Merck (MRK) United States $205.072B 17.77
Novartis AG (NVS) Switzerland $203.357B 17.38
AbbVie (ABBV) United States $137.681B 12.22
Eli Lilly (LLY) United States $120.583B 21.20
Sanofi (SNY) France $113.115B 14.01
Novo Nordisk (NVO) Denmark $107.931B 17.53
AstraZeneca (AZN) United Kingdom $103.013B 12.79
Bristol-Myers Squibb (BMY) United States $88.253B 14.53